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Abstract
Purpose Dysphagia (swallowing dysfunction) is a debilitating,
depressing, and potentially life-threatening complication
in cancer patients that is likely underreported. The present
paper is aimed to review relevant dysphagia literature
between 1990 and 2010 with a focus on assessment
tools, prevalence, complications, and impact on quality
of life in patients with a variety of different cancers,
particularly in those treated with curative chemoradiation for
head and neck cancer.
Methods The literature search was limited to the English
language and included both MEDLINE/PubMed and
EMBASE. The search focused on papers reporting dysphagia
as a side effect of cancer and cancer therapy. We identified
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articles identified in references.
Results Awide range of assessment tools for dysphagia was
identified. Dysphagia is related to a number of factors such
as direct impact of the tumor, cancer resection, chemother-
apy, and radiotherapy and to newer therapies such as epi-
dermal growth factor receptor inhibitors. Concomitant oral
complications such as xerostomia may exacerbate subjective
dysphagia. Most literature focuses on head and neck cancer,
but dysphagia is also common in other types of cancer.
Conclusions Swallowing impairment is a clinically relevant
acute and long-term complication in patients with a wide
variety of cancers. More prospective studies on the course of
dysphagia and impact on quality of life from baseline to
long-term follow-up after various treatment modalities,
including targeted therapies, are needed.
Keywords Dysphagia.Aspiration.Swallowing
dysfunction.Cancer.Headandneckneoplasms.
Chemoradiation.Deglutitiondisorders
Introduction
Swallowing of food and liquids including saliva is a com-
plex biomechanical interaction of physiology and anatomy
that occurs in four stages: oral preparatory, oral, pharyngeal,
and esophageal [1, 2]. The oral phases of swallowing are
voluntary, followed by an involuntary reflex, requiring fast
and precise coordination between sensory input and motor
function controlled by the medulla in the brain stem and by
the cerebral cortex. The material being swallowed is a critical
factor in determining the type of swallow. For example, as the
volume increases, the duration and width of opening of the
upper esopharyngeal sphincter as well as the duration of
airway closure increase [3]. Similarly, viscosity of the bolus
affects the swallowing process. Six cranial nerves and over 25
musclesareinvolved,andany neurological orstructural defect
affects swallowing. This may result in dysphagia (swallowing
dysfunction), a symptom indicating a delay in the passage of
solids or liquids from the oral cavity to the stomach.
Dysphagia and odynophagia (painful swallowing) are
common in cancer patients. Most studies on this complica-
tion are performed in patients with head and neck cancers
(HNC), but swallowing disorders may also develop in
patients with other malignancies. The current narrative re-
view will summarize current literature on dysphagia in
cancer aimed to inform health care professionals on this
debilitating and potentially life-threatening complication.
We will focus on assessmenttools,prevalence, complications,
and impact on quality of life in patients with a variety of
different cancers, particularly in those treated with curative
chemoradiation (CRT) for HNC. In addition, future directions
of research in this area will be discussed.
Methodology
A research librarian performed literature searches using
MEDLINE/PubMed and EMBASE. Search terms included
dysphagia, odynophagia, aspiration, swallowing dysfunc-
tion, esophagitis, cancer, head and neck neoplasms, chemo-
radiation, targeted therapies, deglutition, deglutition
disorders. The period searched was between 1990 and
2008, with an updated search completed by the Section
Head (JRD) from 2008 to 2010, which included MEDLINE,
EMBASE, and SCOPUS databases and a search of the
references of relevant articles. The search focused on studies
reporting dysphagia as a side effect of cancer and cancer
therapy. Searches were limited to studies involving human
subjects that were published in English. Both original re-
search and review articles were considered for inclusion in
this narrative review. The majority of the papers involved
patients with HNC, but a limited number of papers
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Dysphagia assessment
Assessment of dysphagia typically includes both clinical
and instrumental evaluations, whereas in some studies, the
presence of a feeding tube or dietary changes are used as
surrogate markers for dysphagia [4].
Clinical swallowing examination includes a medical his-
tory, oral/oropharyngeal examination, and swallow trials.
Key indicators of swallowing problems include a history
of swallowing complaints, incidents of coughing/choking or
regurgitation, difficulty or avoidance of some food consis-
tencies, poor nutrition, presence of a feeding tube, any prior
oral/oropharyngeal resection or chemoradiation, history of
pneumonia or respiratory disease, and any prior neurologi-
cal problems. Oral/oropharyngeal examination involves in-
spection of the oral cavity and oral health including dental
status (number of teeth, caries, periodontal disease), dental
prosthesis, oral dryness, as well as evaluation of the
strength, motion, and symmetry of the tongue, lips, jaws,
and soft palate. Furthermore, sensory perception of the lips,
cheeks, palate, tongue, and pharynx is evaluated. Observing
symptomatic dysphagia includes a swallowing test, which
incorporates trials of various food and fluid consistencies.
Bolus size and characteristics (taste, temperature) can be
modified to examine any change. Multiple swallows may
be observed to explore fatigue effects throughout a meal.
Level of swallowing disability as determined from the
clinical bedside assessment can be quantified using the
Royal Brisbane Outcome Measure for Swallowing (RBHOMS)
[5]. The RBHOMS is a swallowing disability rating scale,
designed to monitor difficulties in everyday swallowing func-
tion based on clinical indicators of swallowing, not specific
diet/fluid consistencies. Psychometric analysis reveals it to be
a valid clinical tool for documenting change in swallowing
disability over time and across patients with different etiologies.
Objective assessment of swallowing function and swal-
low safety is frequently performed using videofluoroscopy
of swallowing (VFSS). It allows radiographic assessment of
the structures and dynamics involved in all phases of the
swallowing process. This procedure is often referred to as
modified barium swallow (MBS), which is a validated in-
strument developed by Logemann and coworkers [6].
Patients are given measured volumes, and viscosities of
food and the findings are scored with the Swallowing Per-
formance Status Scale (SPS) [7], which provides an accurate
assessment of the presence and severity of dysphagia and
aspiration risk by combining clinical and radiographic data
(Table 1). The Dysphagia Outcome and Severity Scale may
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Support Care Cancer (2012) 20:433–443 435be used to document functional outcomes and diet status [8].
The penetration–aspiration scale encompasses an 8-point,
equal-appearing interval scale to describe penetration and
aspiration events [9]. In addition, the oropharyngeal swal-
low efficiency is a global measure of the safety and the
speed of the swallow which is determined by measuring
the percentage of bolus swallowed into the esophagus di-
vided by the total (oral and pharyngeal) transit time. VFSS
can be combined with conventional or high-resolution ma-
nometry, which permits correlation of the motility of ana-
tomic structures with the resulting intraluminal pressure
patterns. Another objective tool is Fiberoptic Endoscopic
Evaluation of Swallowing (FEES). FEES visualizes the
pharynx using a transnasal endoscopic tube and detects
premature food or fluid leakage from the oral cavity with
increased risk for aspiration, but it does not provide infor-
mation on the oral stages of swallowing. FEES can be
combined with sensory testing (FEESST). Direct endoscopy
under anesthesia can be used to visualize (and dilate) stric-
tures in more inferior parts of the pharynx. Computed to-
mography (CT) scans have a role in evaluating radiation
therapy (RT)-induced thickness of several swallowing struc-
tures. Advances have been made in the digital processing of
videofluoroscopic or endoscopic evaluation to derive objec-
tive measurements [10]. In addition, predictive modeling
has now become available for swallowing dysfunction [11].
A number of patient- and clinician-rated scales have been
developed to assess subjective dysphagia and its impact on
quality of life (QOL) in cancer patients. The Swallowing
Questionnaire Quality of Life questionnaire (SWAL-QOL
and SWAL-CARE) [12] and the MD Anderson Dysphagia
Inventory (MDADI) are validated dysphagia-specific QOL
instruments. The SWAL-QOL is a 44-item QOL instrument
that defines cutoff scores aimed to identify patients with
dysphagia [13]. The MDADI is a validated dysphagia-
specific QOL instrument consisting of 20 questions with
global, emotional, functional, and physical subscales. Other
instruments with subscales or domains on dysphagia and
QOL include the European Organization for Research and
Treatment of Cancer (EORTC) QLQ C-30 (global quality of
life scale) and Head and Neck Module, the Performance
Status Scale for HNC patients (PSS-H&N) [14], the Func-
tional Assessment of Cancer Therapy Head and Neck Mod-
ule (FACT-H&N) [14, 15], the University of Washington
Quality of Life Revised (UW-QOL-R) [16], the Head and
Neck Cancer Inventory (HNCI) [17], and the University of
Michigan Head and Neck Quality of Life survey (HNQOL)
[18]. The Oral Mucositis Daily Questionnaire (OMDQ) [19]
and the Oral Mucositis Weekly Questionnaire-Head and
Neck (OMWQ-HN) are validated scales that have been
developed to assess mucositis-associated mouth and throat
pain, as well as its impact on function (including swallow-
ing) and overall well-being [20]. Recently, the Vanderbilt
Head and Neck Symptom Survey (VHNSS) has been vali-
d a t e dt os c r e e nf o rs y m p t o m s , including swallowing in
HNC patients treated with chemoradiation [21], and the
Sydney Swallow Questionnaire (SSQ) has been developed
to assess self-reported physiological oral and pharyngeal
swallowing function [22]. In addition, acute and chronic
dysphagia can be assessed using the Common Terminology
Criteria for Adverse Events (CTCAE) and the Radiation
Therapy Oncology Group/European Organization for Re-
search and Treatment of Cancer's (RTOG/EORTC) Acute
and Late Radiation Morbidity Scoring System. The Therapy
Outcome Measure (TOM) is a clinician-rated instrument
that comprises ten scales relating to a range of communica-
tion and swallowing disorders [23]. The Head and Neck
Performance Status Scale (HNPS) is also a clinician-rated
instrument evaluating speech, normalcy of diet, and eating
in public [24].
There is discrepancy in the literature with respect to the
correlation between subjective and objective swallowing
evaluation. For example, Pauloski et al. [25] reported excel-
lent correlation between swallow function assessed by VF
and patient-reported dysphagia. In contrast, Jensen et al.
[26] found little concordance between dysphagia-related
complaints and objective parameters. Objective evaluation
may underestimate dysphagia severity experienced by
patients. In reverse, patients may not report any difficulty
with swallowing, but silent aspiration may occur without
coughing [27]. In addition, patients may not necessarily
show abnormality in all aspects of swallowing [28]. Thus,
combining several subjective and objective evaluation tech-
niques providing complimentary information is considered
useful.
Swallowing outcomes can be also graded using the In-
ternational Classification of Functioning, Disability and
Health (ICF, WHO) [29]. The ICF describes and measures
health and disability associated with different health condi-
tions. It encompasses three domains describing impairment
of body function or structure (i.e., swallow dysfunction
assessed by VF or MBS), activity limitation (measured by
clinician- or patient-rated scales), and participation restric-
tion (reduced ability to be involved in work or social
situations) [30]. QOL is not part of the ICF classification, but
the ICF can be used to study the complex interrelationships
among functioning, contextual factors, and individuals'
perceptions of their QOL.
Head and neck cancers
The primary treatment modalities for HNC include surgery
and radiotherapy, with an increasing role for chemotherapy
and molecularly targeted therapies. All treatment modalities
436 Support Care Cancer (2012) 20:433–443may result in acute and long-term swallowing dysfunction,
but dysphagia may also be present prior to therapy.
Pre-treatment dysphagia
Dysphagia can be a result of malignancies in the head and
neck region, particularly pharyngeal, tongue, and esophageal
cancers. The frequency and severity of pre-treatment dyspha-
gia and its sequelae (e.g., aspiration) depend on tumor stage
and localization, since the tumor can affect the motility of
structuresinvolvedinswallowing[31–35].Pauloskietal.[31]
reported a prevalence of pre-treatment dysphagia in 28.2% in
patients with stage T2 or more oral cancer, 50.9% in pharyn-
geal cancer, and 28.6% in laryngeal cancer. Other studies also
showed significant rates of pre-treatment dysphagia and aspi-
ration (summarized in Table 2). In addition to dysphagia
caused by the tumor, increased age may be associated with
increased baseline swallowing dysfunction [36]. Patients who
cannot swallow adequately before treatment are at greater risk
for chronic swallowing dysfunction after treatment [27, 37].
However,moststudiesontheprevalenceofchronicdysphagia
begin assessment at 3 months after treatment when acute
effects have resolved whereas prospective studies starting
prior to cancer treatment are necessary to distinguish between
tumor- and treatment-associated dysphagia.
Dysphagia following surgery
Surgical interventions for HNC result in anatomic or neuro-
logic insults with site-specific patterns of dysphagia [38].
Transection of muscles and nerves, loss of sensation, and scar
tissuemayallaffectfunctioningoftissuesvitalforswallowing
[39]. The swallowing deficits that occur after surgical resec-
tions vary with the site of the tumor [40], the size of the tumor
[41], the extent of surgical resection [42], and possibly the
typeofreconstruction[43].Ingeneral,thelargerthe resection,
the more swallowing function will be impaired. However,
resection of structures vital to bolus formation, bolus transit,
andairwayprotectionsuchasthetongue,tonguebase,and the
larynx will have the greatest impact on swallowing function
[44, 45]. Resection of the anterior floor of mouth has been
found to have a limited impact on swallowing function [46],
except when the geniohyoid or myelohyoid muscles are in-
volved [47]. Surgery disrupting the continuity of the mandib-
ular arch without reconstruction has a profound negative
impact on swallowing function. Resection of tumors involv-
ing the palate and maxillary sinus often creates defects that
need reconstruction to restore oral function. Papers by Mittal
etal. [44]and Manikantanetal. [48]p r o v i d ead e t a i l e dr e v i e w
of surgical procedures and dysphagia and aspiration risk.
Improvementsindiagnostictechniquesleadingtorefinements
of indications for surgery and minimally invasive surgical
Table 2 Estimated prevalence of pre-treatment aspiration and aspiration in head and neck cancer patients
Tumor stage Study type Number (N)
of patients/
controls
Dysphagia (%)/
assessment instrument
Aspiration (%)/
assessment
instrument
Reference
T2 or more Prospective
case/contr
352/104 Oral, 28.2%; pharynx,
50.9%; larynx, 28.6%/VFS, MBS
Pauloski et al. [32]
III–IV Retrospective
survey
79/large
normative
group
Mild impairment, 28% Oral, 14% Stenson et al. [33]
Mild–moderate impairment, 34% Oropharynx, 30%
Moderate–severe, 4% Larynx, 67%
VFS, MBS, SPS Hypopharynx, 80%
VFS
III–IV Prospective
observational study
27/no contr 41% Rosen et al. [106]
VFS
IV Prospective
observational study
22 14% Eisbruch et al. [88]
VFS
II–IV Retrospective study 63 71.5%, grade 1–3; 17.5%,
grade 4–5; 11%, grade 6–7/
MBS, SPS
17% Nguyen et al. [107]
MBS/VFS
III–IV Prospective
observational study
36 8% Feng et al. [86]
VFS
All tumor stages Retrospective study 236 Mild to severe dysphagia: oral,
5%; oropharynx, 33%;
larynx, 29%; hypopharynx, 52%
Nguyen et al. [35]
VFS, MBS, SPS
Contr controls, MBS modified barium swallow procedure, SPS swallowing performance status scale, VFS videofluoroscopy
In part adapted from Platteaux et al. [53]
Support Care Cancer (2012) 20:433–443 437techniques are promising advances to reduce dysphagia in
HNC patients [49].
Dysphagia associated with (chemo)radiation
Primary radiotherapy for HNC is conventionally given up to a
total dose of 70 Gy in daily fractions of 2 Gy, five fractions a
week during 7 weeks. Intensified schedules (hyperfractionation
and/or acceleration) and the use of chemoradiotherapy (CRT)
have been shown to have greater efficacy than surgical treat-
ment in terms of regional control and survival in some cancers,
such as tonsillar, nasopharynx, and base of tongue. CRT has
become the standard of care for HNC where possible [50, 51].
However, organ preservation does not always translate into
preservation of function [44, 52]. CRT regimens have more
acute and chronic side effects as compared to conventional
radiotherapy alone. The severity of radiation-induced dyspha-
gia is dependent on total radiation dose, fraction size and
schedule, target volumes, treatment delivery techniques,
concurrent chemotherapy, genetic factors, percutaneous
endoscopic gastrostomy (PEG) tube or nil per os, smoking,
and psychological coping factors (reviewed by [53]). Patients
with advanced tumors seem less likely to have worsening of
swallowing following CRT [54].
The most common acute oropharyngeal complications in-
clude mucositis, edema, pain, thickened mucous saliva and
hyposalivation, infection, and taste loss, which may all con-
tribute to acute odynophagia and dysphagia. By 3 months
after treatment, acute clinical effects have largely resolved,
and normal swallowing function is restored in the majority of
patients. Unfortunately, a continuing cascade of inflammatory
cytokines triggered byoxidative stress and hypoxia may dam-
age the exposed tissues, and dysphagia may develop even
years after the completion of treatment. Late sequelae that
maycontributetochronicdysphagiaincludereducedcapillary
flow,tissueatrophyandnecrosis,alteredsensation,neuromus-
cular fibrosis leading to trismus and stricture formation, hypo-
salivation, and infection including dental diseases (e.g.,
radiation caries and periodontal attachment loss). Lee et al.
[55] reported the results of a retrospective study of 199
patients treated with CRT. Of 82 patients who underwent
swallowing evaluation, 41 (21% of total) patients were found
to have a stricture. Predictors of stricture formation included
twice-per-day radiation, hypopharyngeal malignancy, and
female sex. Moreover, lymphedema, radiation-induced
damage to neural structures, and genetic predisposition
may play a role in chronic dysphagia [11, 39].
Intensity-modulated radiotherapy (IMRT) has emerged as
an effective technique to deliver the full radiation dose to the
tumor and regions at risk, while reducing exposure of sur-
rounding healthy tissues. Eisbruch and coworkers [56] have
identified dysphagia and aspiration risk structures (DARS).
In particular, damage to the tongue base, pharyngeal
constrictors, the larynx, and autonomic neural plexus was
found to be crucial in the development of post-radiotherapy
dysphagia. Studies confirmed the association between re-
ducing the radiation dose to DARS by IMRT or brachyther-
apy and decreasing the dysphagia risk [11, 57–61]. Roe et
al. [62] performed a systematic review of the literature on
swallowing outcomes following IMRT. Based on the results
of 16 studies (published between 2001 and 2009), a benefit
of IMRT was found, but a meta-analysis was not possible
due to the heterogeneous nature of the studies. A recent
longitudinal long-term follow-up study by Feng et al. [63]
reported that IMRT sparing of DARS did not compromise
locoregional control rates in patients with oropharyngeal
cancer and was effective to reduce chronic dysphagia. Pro-
tection of the glottic larynx via beam-split IMRT techniques
is promising for the prevention of aspiration [64].
Dysphagia associated with epidermal growth factor receptor
inhibitors
Epidermal growth factor receptor (EGFR) is commonly over-
expressed in a variety of cancers including HNC and is an
attractive molecular target. Monoclonal antibodies and small-
molecule inhibitors have been developed to inhibit EGFR
pathways. Cetuximab has been shown to enhance the effects
of radiotherapy and improves survival at 5 years in patients
with advanced HNC [65]. Acne-like skin rash is a frequently
reported side effect of cetuximab, but most reports to date
suggest that mucositis and dysphagia are not increased as
compared to radiotherapy alone [65, 66]. In contrast, a small
study on concurrent RTand cetuximab inpatients withlocally
advanced HNC found more severe mucositis and acute dys-
phagiathanreportedpreviously[67].Inastudythatcombined
panitumumab, carboplatin, and paclixatel with IMRT in
patients with advanced HNC, the incidence of grade 3 muco-
sitis and dysphagia was greater than 94% [68].
Xerostomia and dysphagia
There is evidence of the importance of saliva in the initiation
and the efficiency of swallowing [69]. In normal circumstan-
ces, the swallowing process is initiated when cohesive forces
between food particles in the bolus are strongest [70, 71].
Difficulty inswallowing and riskof choking may arise ifpeak
cohesive force isnot reached because ofalterations insalivary
flow and viscosity. Dysphagia has been reported in patients
with different etiologies of salivary gland dysfunction mea-
sured by patient-reported outcomes and VF [72]. Teguh et al.
[73] found a strong association between dry mouth, thick
saliva, and dysphagia-related QOL. However, hyposalivation
was not associated with objective swallow disturbances
12 months after CRT for HNC; rather, changes in the
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have changed [74].
A meta-analysis [75] evaluating the efficacy of amifos-
tine, a cytoprotectant to reduce damage to salivary glands in
HNC patients treated with radiation, showed a significant
decrease in the prevalence of dysphagia (P00.04; odds
ratio00.26; confidence interval, 0.07–0.92). This may be
an effect of decreased mucosal toxicity leading to less
fibrosis and late dysphagia, rather than an effect of reduced
salivation. Brizel et al. [76] confirmed that the administration
of amifostine may have a modest effect on reducing late
dysphagia in patients treated with (C)RT.
Non-head and neck cancers
Acute as well as chronic dysphagia may develop in any cancer
patient with oropharyngeal mucositis as a result of treatment
toxicity to the esophagus or secondary infection. For example,
acute dysphagia is estimated to occur in up to 20% of patients
after high-dose RT and in up to 40% in patients treated with
concurrent chemotherapy for lung cancer [77, 78]. Dysphagia
may also develop in patients with a wide variety of malignan-
cies treated with targeted therapies. For example, Sonis and
coworkers [79] reported dysphagia in 8.5% of patients who
developed mammalian target of rapamycin-associated stomati-
tis. In selected cases, swallowing may be affected by the tumor
itself. This is reported to occur in a small percentage of patients
with lung cancer, but because of the frequency of this cancer, a
largenumbermaybeaffected.Themostcommoncauseoflung
cancer-related dysphagia is mediastinal disease compressing
the esophagus [80].
Metastatic breast cancer may occasionally involve the gas-
trointestinal tract and may cause swallow problems. Lobular
breast carcinoma is most likely to metastasize into the oro-
pharynx or the esophagus [81]. Dysphagia has also been
described as a presenting symptom of thyroid cancer [82]o r
as a late side effect of treatment with radioactive iodine [83].
Swallowing may be impaired in patients with acute and
chronic graft-versus-host disease (GVHD), as a result of bul-
lous esophagitis [84]. In addition, chronic GVHD may result in
submucosal fibrosis and occasionally in esophageal strictures.
There may be fibrotic peri-oral skin changes, muscles may be
involved, and salivary production may be impaired. Oropha-
ryngealswallowabnormalitiesassessedbyVFwerealsofound
to be present in allogeneic hematopoietic stem cell transplan-
tation (HSCT) recipients without chronic GVHD [85].
Complications
Dysphagia may predispose to aspiration (defined as swal-
lowing dysfunction once the bolus has passed the vocal
folds) and potentially life-threatening pulmonary complica-
tions [86]. Aspiration usually manifests by coughing or
clearing of the throat before, during, or after swallowing,
but in almost half of HNC patients, the cough reflex is
ineffective or absent [87]. Silent aspiration was found to
be frequent following CRT [88], but this complication as
well as its consequences is underappreciated. Nguyen et al.
[34] reported on 55 patients with locally advanced HNC
treated with CRT; eight patients developed aspiration
pneumonia, which was fatal in five cases. MBS appeared as
au s e f u lt o o lt oa s s e s sa s p i r a t i o nr i s k[ 89].
Dysphagia may contribute to dehydration, which may
eventually affect renal function. Reduced food intake and
unfavorable dietary changes may lead to malnutrition and
decreased resistance to infection. Prolonged feeding by a
nasogastric feeding tube or a PEG tube may be necessary. In
turn, this may contribute to sustained dysphagia, because of
muscle atrophy [52, 90]. Difficulties with speaking, eating
and drinking, or drooling may affect emotional health and
put patients and family members in social isolation. Opioids
for the management of odynophagia may contribute to
hyposalivation and constipation.
Impact on quality of life
QOL reflects the health status of patients by assessing
symptoms and functioning and the psychosocial response
to possible limitations. Odynophagia and dysphagia and
their complications may result in a marked decrease of
overall QOL and health-related (HR)QOL. Eating and
drinking may become difficult or even impossible, give no
pleasure, and absorb a long time. The ability of taking
different types of food may be hampered, and problems with
eating in public may be experienced, all of which may result
in isolation and depressive symptoms. The presence of a
feeding tube has been shown to be a powerful predictor of
QOL 1 year post-treatment. Tube feeding is time consuming
and is associated with significant costs [91]. Patients treated
with CRT for oropharyngeal tumors had better emotional
and functional scores of subscales of the MDADI than
patients who underwent surgery followed by RT [92]. Teguh
and coworkers [73] performed a study on the dose admin-
istered to swallowing structures and swallowing-related
QOL. They found a clear dose–effect relationship for radi-
ation to the superior constrictor muscle and long-term swal-
lowing outcomes and QOL. Langendijk and coworkers [93]
found HRQOL to be more seriously affected by swallowing
disorders than by comparable grades of xerostomia, partic-
ularly in the first 12 months after completion of CRT for
HNC. IMRT reduced morbidity including dysphagia and
improved HRQOL in a prospective long-term follow-up
study [94]. One study found dysphagia contributing to
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12 months, but not completely up to baseline levels in
patients who underwent surgery for HNC [95]. Dysphagia
in HNC has a significant impact on QOL not only in patients
but also in their caregivers [96]. Dysphagia is also known as
a barrier for patients to return to work after treatment [97]. A
gradual worsening of symptoms including dysphagia has
been reported by patients treated with high-dose CRT for
lung cancer, but this had no clear impact on the overall QOL
at 18 months [98].
Several limitations should be noted with respect to QOL
studies in patients with HNC and other cancers. Many trials
only report clinician-rated CTCAE scores ≥3, which may
not provide an adequate estimate of the burden of dysphagia
[99]. Furthermore, tumor- and treatment-related symptom
control issues affect the domains of physical and functional
well-being, whereas differences in coping capacity may
result in less consistent effects of these symptoms on social
and emotional well-being [100]. In addition, dysphagia is
not an isolated symptom; it rather manifests as a symptom
complex that includes numerous components (e.g., oropha-
ryngeal or esophageal pain, speech impairment, dry mouth,
taste alterations, the presence of a feeding tube, coughing,
pulmonary complications, altered self-image).
Concluding remarks and future directions
Swallowing impairment is a clinically relevant acute and
long-term complication in patients with a variety of different
cancers, particularly in those treated with curative CRT for
HNC. It is important to note that CRT, which is considered
to be “organ-sparing” as compared to radical surgery, does
not necessarily translate into functional preservation.
Swallowing problems have a multifactorial and complex
etiology, and our current insight into the prevalence of
swallowing dysfunction in cancer patients is still limited.
Most studies are performed in HNC patients, but the hetero-
geneous nature of studies with respect to design, inclusion
criteria, and dysphagia assessment makes it difficult to ob-
tain a clear insight in the prevalence and severity of dyspha-
gia and aspiration after different treatment modalities. These
conditions are likely underreported [52, 98]. Instrumental
testing is crucial before, during, and after CRT in HNC
patients to document swallow function and diagnose aspi-
ration, but also, patient-reported measurements should be
included. Clinicians tend to assign a lower grade of severity
than patients, and even low observer-reported dysphagia
rates might represent clinically significant dysphagia [100].
There is a clear need to perform prospective studies on the
course of swallow functioning and impact on QOL from
baseline to long term after various (new) HNC treatment
modalities as well as in patients with non-HNC, particularly
in those who underwent allogeneic HSCT.
Radiation therapy to the head and neck area can result in
acute and long-term dysphagia that may increase in severity
over time even years after the completion of radiotherapy.
Advances in radiation therapy leading to more accurate delin-
eation of radiation targets inthe head and neck isan important
area of investigation since this may result in better tumor
control and promises reduced toxicity [57]. In addition, the
use of radioprotectors such as amifostine may improve
swallow outcomes. The addition of chemotherapy can
increase acute toxicity including swallowing problems.
Data are inconclusive whether the addition of chemother-
apy results in an increased risk of long-term dysphagia.
Studies are needed to determine whether acute inflammation
associated with oropharyngeal mucositis predisposes for late
dysphagia. Pauloski et al. [101] reported that impaired oral
intake in the first year post-CRTwas associated with chronic
mucosal changes. There is recent evidence from an experi-
mental study that RT-induced mucositis is associated with
fibrosis [102]. Exuberant fibrosis results in a loss of elastic-
ity that may contribute to detrimental functional consequen-
ces, including acute and late dysphagia [39]. Agents capable
of ameliorating RT- and CT-induced mucositis, particularly
those that decrease inflammation and the pathogenic fibrotic
repair response, may minimize late complications, including
swallowing problems. More research should also be per-
formed to determine the impact of molecular targeted
therapies on swallow function in HNC patients and non-
HNC patients.
Management of swallowing disorders is beyond the
scope of the review, but needs evidence-based data to for-
mulate multidisciplinary supportive care approach [103]. A
systematic review indicated a positive effect of involvement
of speech-language pathologists in the prevention and treat-
ment of oropharyngeal dysphagia in cancer and non-cancer
patients [28].
Screening in clinical practice to identify patients who
may be in need of swallow rehabilitation should be per-
formed routinely, but ideally, efforts are aimed at identifying
risk patients and developing cost-effective preventative
measures. Langendijk et al. [11] developed a predictive
model for dysphagia risk after curative (C)RT. Werbrouck
[60] found dose-related parameters as well as genetic poly-
morphisms in DNA repair genes to be predictive for acute
dysphagia. More studies into genetic profiles associated
with enhanced or reduced toxicity risk are warranted. Sonis
[104] suggested that when a patient develops one compli-
cation as a result of cancer treatment, it is likely that he/she
will develop other toxicities in a predictable pattern [105].
Studies into symptom clusters of acute and chronic toxicities,
including C(RT), and targeted therapy-induced dysphagia
may help to better understand common pathobiological
440 Support Care Cancer (2012) 20:433–443mechanisms, which may lead to more effective management
strategies. Looking at symptom clusters rather than at isolated
symptomsseems alsoimportant toevaluatethe total burdento
patients and to estimate costs.
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